| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083163 | Drug Discovery Today: Therapeutic Strategies | 2006 | 6 Pages |
Abstract
Human cytomegalovirus (HCMV) infection in immunodeficient patients is frequently associated with life-threatening invasive visceral disease. Control of persistent infection and the recovery from HCMV disease essentially depends on the host's cell-mediated immune response. Therefore, adoptive T-cell therapy is of substantial interest in care of immunodeficient patients. Here, we review the therapeutic application of HCMV-specific T-cells to fight HCMV infection.
Section editors:Claudine Bruck – GlaxoSmithKline, King of Prussia, USAMichel Goldman – University of Brussels, Brussels, Belgium
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ulrich Grigoleit, Markus Kapp, Hermann Einsele,